| High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants P Razavi, BT Li, DN Brown, B Jung, E Hubbell, R Shen, W Abida, K Juluru, ... Nature medicine 25 (12), 1928-1937, 2019 | 541 | 2019 |
| Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ... Cancer cell 34 (6), 893-905. e8, 2018 | 364 | 2018 |
| Genomic characterization of primary invasive lobular breast cancer C Desmedt, G Zoppoli, G Gundem, G Pruneri, D Larsimont, M Fornili, ... Journal of clinical oncology 34 (16), 1872-1881, 2016 | 306 | 2016 |
| Principles governing A-to-I RNA editing in the breast cancer transcriptome D Fumagalli, D Gacquer, F Rothé, A Lefort, F Libert, D Brown, ... Cell reports 13 (2), 277-289, 2015 | 204 | 2015 |
| Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations D Brown, D Smeets, B Székely, D Larsimont, AM Szász, PY Adnet, ... Nature communications 8 (1), 14944, 2017 | 168 | 2017 |
| Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium BT Li, F Janku, B Jung, C Hou, K Madwani, R Alden, P Razavi, ... Annals of oncology 30 (4), 597-603, 2019 | 138 | 2019 |
| Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer DN Brown, I Caffa, G Cirmena, D Piras, A Garuti, M Gallo, S Alberti, ... Scientific reports 6 (1), 19435, 2016 | 132 | 2016 |
| Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial N Riaz, E Sherman, X Pei, H Schöder, M Grkovski, R Paudyal, N Katabi, ... JNCI: Journal of the national cancer institute 113 (6), 742-751, 2021 | 120 | 2021 |
| Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors P Razavi, MN Dickler, PD Shah, W Toy, DN Brown, HH Won, BT Li, ... Nature cancer 1 (4), 382-393, 2020 | 114 | 2020 |
| Immune infiltration in invasive lobular breast cancer C Desmedt, R Salgado, M Fornili, G Pruneri, G Van den Eynden, ... JNCI: Journal of the national cancer institute 110 (7), 768-776, 2018 | 109 | 2018 |
| Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors F Pareja, AH Brandes, T Basili, P Selenica, FC Geyer, D Fan, ... Nature communications 9 (1), 3533, 2018 | 107 | 2018 |
| Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS A Rose Brannon, G Jayakumaran, M Diosdado, J Patel, A Razumova, ... Nature communications 12 (1), 3770, 2021 | 96* | 2021 |
| Uncovering the genomic heterogeneity of multifocal breast cancer C Desmedt, D Fumagalli, E Pietri, G Zoppoli, D Brown, S Nik‐Zainal, ... The Journal of pathology 236 (4), 457-466, 2015 | 84 | 2015 |
| HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2 AB Hanker, JT Garrett, MV Estrada, PD Moore, PG Ericsson, JP Koch, ... Clinical cancer research 23 (15), 4323-4334, 2017 | 81 | 2017 |
| Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology D Fumagalli, A Blanchet-Cohen, D Brown, C Desmedt, D Gacquer, ... BMC genomics 15, 1-12, 2014 | 81 | 2014 |
| The genomic landscape of mucinous breast cancer F Pareja, JY Lee, DN Brown, S Piscuoglio, R Gularte-Mérida, P Selenica, ... JNCI: Journal of the national cancer institute 111 (7), 737-741, 2019 | 77 | 2019 |
| Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer C De Angelis, X Fu, ML Cataldo, A Nardone, R Pereira, J Veeraraghavan, ... Clinical cancer research 27 (17), 4870-4882, 2021 | 63* | 2021 |
| Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC) S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, DN Brown, ... Cancer research 73 (24 Supplement), S1-05-S1-05, 2013 | 61* | 2013 |
| Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers D Fumagalli, TR Wilson, R Salgado, X Lu, J Yu, C O'Brien, K Walter, ... Annals of oncology 27 (10), 1860-1866, 2016 | 57 | 2016 |
| Whole-exome sequencing analysis of the progression from non–low-grade ductal carcinoma in situ to invasive ductal carcinoma F Pareja, DN Brown, JY Lee, A Da Cruz Paula, P Selenica, R Bi, ... Clinical cancer research 26 (14), 3682-3693, 2020 | 53 | 2020 |
